Role of Removed Lymph Nodes on the Prognosis of M0 Small-Bowel Neuroendocrine Tumors: a Propensity Score Matching Analysis from SEER Database
-
Published:2021-06-09
Issue:12
Volume:25
Page:3188-3197
-
ISSN:1091-255X
-
Container-title:Journal of Gastrointestinal Surgery
-
language:en
-
Short-container-title:J Gastrointest Surg
Author:
Xie Jie-binORCID, Pang Yue-shanORCID, Li XunORCID, Wu Xiao-tingORCID
Abstract
Abstract
Background
Current studies on the number of removed lymph nodes (LNs) and their prognostic value in small-bowel neuroendocrine tumors (SBNETs) are limited. This study aimed to clarify the prognostic value of removed LNs for SBNETs.
Methods
SBNET patients without distant metastasis from 2004 to 2017 in the SEER database were included. The optimal cutoff values of examined LNs (ELNs) and negative LNs (NLNs) were calculated by the X-tile software. Propensity score matching (PSM) was done to match patients 1:1 on clinicopathological characteristics between the two groups. The Kaplan-Meier method with log-rank test and multivariable Cox proportional-hazards regression model were used to evaluate the prognostic effect of removed LNs.
Results
The cutoff values of 14 for ELNs and 9 for NLNs could well distinguish patients with different prognoses. After 1:1 PSM, the differences in clinicopathological characteristics between the two groups were significantly reduced (all P > 0.05). Removal of more than one LN significantly improved the prognosis of the patients (P < 0.001). The number of lymphatic metastasis in the sufficiently radical resection group (SRR, 3.74 ± 3.278, ELN > 14 and NLN > 9) was significantly more than that in the insufficiently radical resection group (ISRR, 2.72 ± 3.19, ELN < 14 or NLN < 9). The 10-year overall survival (OS) of the SRR was significantly better than that of the ISRR (HR = 1.65, P = 0.001, 95% CI: 1.24–2.19).
Conclusion
Both ELNs and NLNs can well predict the OS of patients. Systematic removal of more than 14 LNs and more than 9 NLNs can increase the OS of SBNET patients.
Funder
the Cooperative Fund of Nanchong Government and North Sichuan Medical College
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Surgery
Reference29 articles.
1. Bilimoria, K. Y., Bentrem, D. J., Wayne, J. D., Ko, C. Y., Bennett, C. L., & Talamonti, M. S. (2009).Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg, 249(1), 63-71. https://doi.org/10.1097/SLA.0b013e31818e4641. 2. Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., et al. (2017).Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol, 3(10), 1335-1342. https://doi.org/10.1001/jamaoncol.2017.0589. 3. Fraenkel, M., Kim, M., Faggiano, A., de Herder, W. W., & Valk, G. D. (2014).Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer, 21(3), R153-R163. https://doi.org/10.1530/ERC-13-0125. 4. Dogeas, E., Magallanes, M., Porembka, M. R., Wang, S. C., Yopp, A. C., Polanco, P. M., et al. (2019).Neuroendocrine Tumors in Meckel's Diverticulum: Recommendation for Lymphadenectomy Regardless of Tumor Size Based on the NCDB Experience. J Gastrointest Surg, 23(4), 679-685. https://doi.org/10.1007/s11605-018-04096-7. 5. Motz, B. M., Lorimer, P. D., Boselli, D., Hill, J. S., & Salo, J. C. (2018).Optimal Lymphadenectomy in Small Bowel Neuroendocrine Tumors: Analysis of the NCDB. J Gastrointest Surg, 22(1), 117-123. https://doi.org/10.1007/s11605-017-3524-9.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|